CYBN:CC News and Press, CYBIN INC. From 09/21/23

- Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies - - Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval - - P...

2023-09-19 08:00:18 ET FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – September 19, 2023 – Depression is costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twi...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has received notification that the United States Patent and Trademark Office (“USPT...

- Newly granted U.S. patent further strengthens the Company’s leadership position in the deuterated tryptamine space - - With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent will add to the most impressive intellectual property portfolio ...

Canadian Investment Regulatory Organization Trade Resumption - CYBN Canada NewsWire TORONTO , Aug. 28, 2023 /CNW/ - Trading resumes in: Company: CYBIN INC. NEO Exchange Symbol: CYBN All Issues: Yes Resumption (ET): 11:05 AM CIRO ca...

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy - - Combined portfolio creates the indust...

Canadian Investment Regulatory Organization Trading Halt - CYBN Canada NewsWire TORONTO , Aug. 28, 2023 /CNW/ - The following issues have been halted by CIRO: Company: CYBIN INC. NEO Exchange Symbol : CYBN All Issues: Yes Reason: Pending News Halt...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, announced that it has renewed its previously established at-the-market equity program. The &#x...

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it ha...

Cybin (NYSE American: CYBN) (NEO: CYBN) was featured in a recent interview with Proactive Investors that covers protection of the company’s IP with the granting of a second U.S. patent for its its deuterated analog programs. Cybin CEO Doug Drysdale joined Steve Darling from Proactive to...